Keraxidil

ID: keraxidil

Aliases: tyrosinase-cleaved minoxidil concept

Type: compound_or_designed_program

Route/form: topical or route depends on product/study

Status: unresolved

Evidence level: unresolved

Best data tier: unresolved identity; adjacent human controlled/review

Support scope: human, review/regulatory

Source types: meta_analysis, review

Linked sources: 2

Broad outcomes: Hair / alopecia

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• minoxidil pathway
• tyrosinase-activated prodrug

Optimization domains

• hair
• prodrug design

Research basis

• Tyrosinase-activated prodrug strategies are real in melanoma chemistry, so the targeting concept is not impossible.
• Hair-follicle localization would be attractive if chemistry and activation were proven.

Limits, risks, and missing evidence

• No primary paper for Keraxidil identity/effect was found in this seed pass.
• Minoxidil activation usually centers on sulfotransferase biology, so tyrosinase-cleavage claims need chemical proof.

Risk flags

• unresolved identity
• no primary source found

Linked papers, labels, and reviews

1. Tyrosinase activated melanoma prodrugs
   review / pubmed_tyrosinase_prodrugs_2009
   General tyrosinase-activated prodrug strategy.
2. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis
   meta_analysis / pubmed_minoxidil_aga_meta_2017
   Parent-drug human evidence for minoxidil in androgenetic alopecia; only indirectly relevant to tyrosinase-cleaved minoxidil prodrug ideas.